PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect PMV Pharmaceuticals to post earnings of ($0.37) per share for the quarter.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.08). On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
PMV Pharmaceuticals Price Performance
PMV Pharmaceuticals stock traded down $0.00 during mid-day trading on Friday, reaching $1.00. 73,999 shares of the company traded hands, compared to its average volume of 244,730. PMV Pharmaceuticals has a fifty-two week low of $0.82 and a fifty-two week high of $2.26. The firm's fifty day moving average is $1.12 and its two-hundred day moving average is $1.38. The company has a market capitalization of $51.78 million, a price-to-earnings ratio of -1.00 and a beta of 1.49.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.
Check Out Our Latest Stock Report on PMV Pharmaceuticals
PMV Pharmaceuticals Company Profile
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Featured Stories
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
